Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Stock Rated “Buy” by Sell-Side Brokerages

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has received a consensus recommendation of “Buy” from the thirteen research firms that are presently covering the company, Marketbeat reports. Eleven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $43.44.

AAPG has been the subject of several analyst reports. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. William Blair began coverage on shares of Ascentage Pharma Group International in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Citigroup assumed coverage on shares of Ascentage Pharma Group International in a report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 price objective on the stock. Citizens Jmp started coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 price objective on the stock. Finally, JPMorgan Chase & Co. lowered their target price on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a report on Thursday, October 8th.

Ascentage Pharma Group International Trading Down 2.7%

AAPG stock traded down $0.40 during midday trading on Tuesday, reaching $14.62. The stock had a trading volume of 8,736 shares, compared to its average volume of 7,873. Ascentage Pharma Group International has a twelve month low of $13.46 and a twelve month high of $34.50. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. The business has a fifty day simple moving average of $15.36 and a two-hundred day simple moving average of $19.61.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million for the quarter. As a group, sell-side analysts predict that Ascentage Pharma Group International will post -2.43 earnings per share for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.